IPSC
Century Therapeutics, Inc.
Key Financials
Operating Income
$-17269000
↑ 87.5%
Net Income
$-9580000
↑ 92.4%
Total Assets
$223.7M
↓ 36.7%
Shareholders' Equity
$158.9M
↓ 1.5%
Total Liabilities
$64.8M
↓ 66.2%
Revenue
$109.2M
↑ 1556.8%
Cash & Equivalents
$61.9M
↑ 5.8%
EPS (Diluted)
$-0.14
↑ 91.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/19/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
| DEFA14A | 4/27/2026 | View on SEC |
| DEF 14A | 4/27/2026 | View on SEC |
| ARS | 4/16/2026 | View on SEC |
| PRE 14A | 4/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IPSC |
| Company Name | Century Therapeutics, Inc. |
| CIK | 1850119 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 215-981-4000 |